Such a great article by Mitch Leslie in @science.org about the potential of inhibiting LINE-1 RT – a genomic, virus-like repetitive element – to address a spectrum of diseases, including ROME’s focus: #neurodegenerative and #autoimmune diseases. www.science.org/content/arti... #darkgenome

Could blocking ‘jumping genes’ help fight disease and aging?

The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own

science.org

Thrilled to announce this publication – many congrats to all of the ROMANS who contributed to this landmark research & to our esteemed academic collaborators, too! Targeting LINE-1 RT may be key to addressing unmet needs for many diseases. We’re proud to be a #darkgenome & LINE-1 RT pioneer! Rosana

ROME Therapeutics@rometx.bsky.social · last yr.

We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...

We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...

Hello, Bluesky! We’re excited to be part of the growing science and biotech community here. We’ll see many of you at #JPM25. #BioSky